Routine Rh testing and RhIg administration are no longer recommended before 12 weeks of gestation for medication abortion, uterine aspiration, or early pregnancy loss, a shift now aligned across SFP, ACOG, WHO, and NAF. This scenario covers the evidence behind the change, the exceptions where testing still applies, how to respond when a patient requests testing anyway, and why it’s worth reviewing standing orders if your practice still screens everyone before a first-trimester abortion.
The scenario:
A 29-year-old G2P1 (she/they) presents for medication abortion at 8 weeks of gestation, consistent with a 6-week ultrasound demonstrating a single intrauterine pregnancy. She reports, “I think I got a shot after I had my son. Do I need a shot before I take the pills?”
She reports her previous pregnancy was uncomplicated. She is not certain of her prior Rh status. She is not certain about a desire for future pregnancies.
What do current guidelines recommend for Rh testing in early pregnancy?
The short answer: routine Rh testing and RhIg administration are no longer recommended before 12 weeks of gestation for patients undergoing spontaneous, medication, or uterine aspiration abortion. This applies to patients seeking care in person and via telehealth. Guidelines from the Society of Family Planning (SFP), American College of Obstetrician Gynecologists (ACOG), World Health Organization (WHO), National Abortion Federation (NAF), and others are based on research demonstrating that before 12 weeks of gestation, it is highly unlikely to develop Rh(D) antibody, given data showing that fetal red blood cell exposure is below the calculated threshold required to cause maternal Rh sensitization.
What’s the evidence behind the change?
The historical recommendation for routine RhIg in early pregnancy was based on extrapolation from term pregnancy data, not direct evidence that first-trimester fetal-maternal red blood cell transfer occurs at levels sufficient to cause sensitization. Historical evidence that fetal red blood cell exposure during early spontaneous or induced abortion can cause maternal Rh sensitization is limited.
More recent studies using flow cytometry, a more sensitive method than older Kleihauer-Betke testing, found that circulating fetal red blood cells in patients after first-trimester pregnancy loss or abortion are below the threshold believed necessary to trigger Rh alloimmunization. These findings, combined with the longstanding lack of evidence that routine early RhIg administration reduces alloimmunization rates, provided the basis for guidelines across multiple organizations.
Are there situations where Rh testing or RhIg is still recommended before 12 weeks?
Yes. For patients with an ectopic pregnancy, sharp curettage, or other procedures associated with a plausible elevated risk of fetomaternal hemorrhage, Rh testing and RhIg should be considered.
After 12 weeks, Rh testing and RhIg administration in Rh-negative patients remain indicated for abortion and pregnancy loss. If a patient’s fetus is known or reasonably certain to be Rh-negative, RhIg is not indicated at any gestational age. As part of shared decision-making, patients who do not wish to receive blood products or do not desire future fertility may decline testing or treatment.
What about patients who want the testing or shot anyway?
Some patients will have strong preferences, prior counseling from other providers, or personal concerns, particularly those who intend future pregnancies. Providers should provide Rh testing and RhIg administration at patient request as part of a shared decision-making process.
The current evidence shows that the risk of Rh sensitization from a first-trimester abortion is low enough that we no longer recommend testing people’s blood type or the injection before 12 weeks of pregnancy. That said, if this is important to you, especially if you might want a pregnancy in the future, I’m happy to go ahead with testing. I want you to feel comfortable with your care.
What does this mean for your workflow?
If you’re in a practice that has been routinely ordering blood type and Rh screen on all patients before first-trimester abortion, it’s worth reviewing your standing orders and preabortion lab protocols.
Key Points
- Routine Rh testing and RhIg administration before 12 weeks of gestation are no longer recommended for patients undergoing medication or aspiration abortion or experiencing early pregnancy loss.
- The evidence base is solid: flow cytometry studies confirm that fetal red blood cell exposure before 12 weeks is below the threshold needed to trigger Rh alloimmunization.
- Guideline alignment across SFP, ACOG, NAF, and WHO is clear and consistent.
- After 12 weeks, Rh testing and RhIg for Rh-negative patients remain indicated.
- Shared decision-making remains a key framework when patients have preferences for testing or treatment that differ from the current care standards.
- If you haven’t already, review and consider updating your practice protocols.
Clinical Tools
- Horvath S, Goyal V, Traxler S, Prager S. Society of Family Planning committee consensus on Rh testing in early pregnancy. Contraception. 2022;114:1–5. doi:10.1016/j.contraception.2022.07.002
- ACOG Clinical Practice Update: Rh D Immune Globulin Administration After Abortion or Pregnancy Loss at Less Than 12 Weeks of Gestation. Obstet Gynecol. 2024;144(6):e140–e143. doi:10.1097/AOG.0000000000005733
- National Abortion Federation. Clinical Policy Guidelines for Abortion Care. 2024. https://prochoice.org/providers/quality-standards/
- Society of Family Planning. Statement on Rh Testing in Early Pregnancy. 2024.
https://societyfp.org/wp-content/uploads/2024/03/Society-of-Family-Planning-Statement-of-Rh-testing-in-early-pregnancy-.pdf